Current Oncology Reports最新文献

Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? 伊维菌素在癌症治疗中的应用：医疗保健提供者应该谨慎还是探索其治疗潜力？

IF 5 2区医学

Current Oncology Reports Pub Date : 2025-07-26 DOI: 10.1007/s11912-025-01704-z

Yash Patel, Jyotsna Chawla, Mayur S Parmar

{"title":"Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?","authors":"Yash Patel, Jyotsna Chawla, Mayur S Parmar","doi":"10.1007/s11912-025-01704-z","DOIUrl":"https://doi.org/10.1007/s11912-025-01704-z","url":null,"abstract":"Purpose of review: This review evaluates the scientific evidence for Ivermectin's potential anticancer properties, an antiparasitic drug garnering interest for oncology applications. It assesses the gap between preclinical and clinical evidence and explores implications for healthcare communication based on current evidence.Recent findings: Preclinical studies (in vitro and animal studies) demonstrate Ivermectin's anticancer effects, including inhibition of cancer cell proliferation, induction of apoptosis, and modulation of signaling pathways (e.g., Wnt/β-catenin, Akt/mTOR) across various cancers. However, clinical evidence in humans is limited, with no large-scale randomized controlled trials (RCTs) confirming therapeutic benefits. Observational studies and case reports highlight the risks of self-medication driven by social media touting Ivermectin's unproven cancer benefits, which can lead to toxicity in oncology patients in some cases. The lack of clinical studies creates a critical translational gap between preclinical results and practical clinical application. Despite promising preclinical data, the absence of conclusive large-scale human clinical evidence limits Ivermectin's utility in cancer treatment. Its affordability appeals in resource-limited settings, but ethical challenges arise from misinformation, which may lead patients to forgo proven therapies. Healthcare providers must communicate responsibly to counter misinformation and guide patients toward evidence-based interventions, while supporting rigorous clinical trials to bridge the preclinical-clinical gap.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon? 循环肿瘤DNA在辅助免疫检查点抑制剂治疗患者中的作用：临床现实还是遥远的地平线？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-07-20 DOI: 10.1007/s11912-025-01701-2

Michele Maffezzoli, Ria Nagpal, Mohamed Elewaily, Lohitha Pedapati, Justin Samuel, Sebastiano Buti, Umberto Malapelle, Akash Maniam, Giuseppe Luigi Banna

引用次数: 0

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-07-12 DOI: 10.1007/s11912-025-01705-y

Tyler Heinrich, Vishal Pandya

引用次数: 0

Correction to: Plant Terpenoids in Combination with Conventional Therapeutics in Colorectal Cancer: A Promising Option. 修正：植物萜类药物联合常规疗法治疗结直肠癌：一个有希望的选择。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-07-08 DOI: 10.1007/s11912-025-01703-0

Chengu Niu, Jing Zhang, Patrick I Okolo

引用次数: 0

Guidelines on Lifestyle Changes and Breast Cancer-where are we up to and how does this Apply to Black Women with Breast Cancer. 生活方式改变与乳腺癌的指导方针我们在做什么以及如何将其应用于患有乳腺癌的黑人妇女。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-28 DOI: 10.1007/s11912-025-01691-1

Sarah D Adomah, Susanne Cruickshank

{"title":"Guidelines on Lifestyle Changes and Breast Cancer-where are we up to and how does this Apply to Black Women with Breast Cancer.","authors":"Sarah D Adomah, Susanne Cruickshank","doi":"10.1007/s11912-025-01691-1","DOIUrl":"https://doi.org/10.1007/s11912-025-01691-1","url":null,"abstract":"Purpose of review: Breast cancer remains a significant health concern globally, with lifestyle factors playing a crucial role in its prevention and management. This paper aims to summarize the current lifestyle guidelines for breast cancer for consistency and consensus of best practice and to explore their specific implications for Black women with breast cancer.Recent findings: There has been a growing body of data from both observational studies and some randomised controlled trials showing the relationship between diet, physical activity, body weight and cancer risk and outcomes. These has led to established national and international guidelines emphasizing the importance of lifestyle advice for survivors in reducing breast cancer risk and a drive for healthcare professionals to guide practice. However, the application and impact of these guidelines can vary across different populations, including Black women, who face unique challenges and disparities in breast cancer outcomes. Breast cancer survivors can benefit from counselling about lifestyle changes across the continuum from diagnosis, treatment through to survivorship. Guidelines recommending these changes for breast cancer survivors have been developed to guide healthcare professionals for consistency and best practice. Culturally sensitive approaches and targeted strategies are crucial to effectively reduce breast cancer disparities and improve survival rates in this population.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hereditary Hematopoietic Malignancies: Considerations for Optimizing Diagnosis and Management. 遗传性造血恶性肿瘤：优化诊断和管理的考虑。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-26 DOI: 10.1007/s11912-025-01699-7

Amy M Trottier, Lea Cunningham, Lucy A Godley

引用次数: 0

Circulating Biomarkers in Sarcoma. 肉瘤中的循环生物标志物。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-17 DOI: 10.1007/s11912-025-01692-0

Taylor P Williams, Valerie P Grignol

引用次数: 0

Artificial Intelligence and Decision-Making in Oncology: A Review of Ethical, Legal, and Informed Consent Challenges. 肿瘤学中的人工智能和决策：伦理、法律和知情同意挑战的回顾。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-17 DOI: 10.1007/s11912-025-01698-8

Eliza-Maria Froicu, Ioana Creangă-Murariu, Vlad-Adrian Afrăsânie, Bogdan Gafton, Teodora Alexa-Stratulat, Lucian Miron, Diana Maria Pușcașu, Vladimir Poroch, Gema Bacoanu, Iulian Radu, Mihai-Vasile Marinca

{"title":"Artificial Intelligence and Decision-Making in Oncology: A Review of Ethical, Legal, and Informed Consent Challenges.","authors":"Eliza-Maria Froicu, Ioana Creangă-Murariu, Vlad-Adrian Afrăsânie, Bogdan Gafton, Teodora Alexa-Stratulat, Lucian Miron, Diana Maria Pușcașu, Vladimir Poroch, Gema Bacoanu, Iulian Radu, Mihai-Vasile Marinca","doi":"10.1007/s11912-025-01698-8","DOIUrl":"https://doi.org/10.1007/s11912-025-01698-8","url":null,"abstract":"Purpose of review: Artificial Intelligence (AI) integration in oncology is transforming therapeutic decision-making by providing clinical decision support. AI may improve treatment precision, but it raises ethical, legal, and informed consent issues. This review examines these paramount AI implementation issues in cancer care. This systematic review followed the PRISMA 2020 guidelines and was prospectively registered in the PROSPERO (CRD420251046482) database. A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane CENTRAL Library to identify studies published between January 2015 and May 2025. AI-supported oncology therapeutic decision-making studies with ethical, legal, or informed consent implications were eligible.Recent findings: Fifteen studies met the inclusion criteria. AI applications were found to support treatment recommendations, personalize drug dosing, and improve adherence and patient management. Despite these benefits, the review highlighted key concerns, including algorithmic transparency, unclear accountability in AI-guided decisions, data privacy, and gaps in patient understanding of AI's role in their care. AI has the potential to enhance oncological care, but ethical and legal issues must be addressed for safe and equitable implementation. Emphasis should be placed on developing robust informed consent models, mitigating algorithmic bias, and establishing clear legal accountability. Future research must establish ethical frameworks and regulatory mechanisms to protect patient autonomy and responsibly integrate AI into oncology.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining the Role of Postoperative Radio-Hormone Therapy in Prostate Cancer. 明确前列腺癌术后放射激素治疗的作用。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-13 DOI: 10.1007/s11912-025-01694-y

Harshitha Dudipala, Mai Dabbas, Kshitij Pandit, Sarika D Gurnani, Rana R McKay

{"title":"Defining the Role of Postoperative Radio-Hormone Therapy in Prostate Cancer.","authors":"Harshitha Dudipala, Mai Dabbas, Kshitij Pandit, Sarika D Gurnani, Rana R McKay","doi":"10.1007/s11912-025-01694-y","DOIUrl":"https://doi.org/10.1007/s11912-025-01694-y","url":null,"abstract":"Purpose of review: Postoperative radio-hormone therapy plays a significant role in management of prostate cancer after radical prostatectomy (RP), particularly in efforts to reduce biochemical recurrence (BCR), distant metastasis, and improve overall survival. BCR rates can be upwards of 50-70% at 5 years, highlighting the need for optimized risk stratification and consideration of multimodal treatment approaches. The purpose of this review is to highlight evidence-based treatment recommendations, and call attention to the importance of personalized therapeutic strategies after RP.Recent findings: Both radiotherapy (RT) and ADT have been shown to optimize survival outcomes and to reduce disease progression in patients with persistent PSA, pathologic lymph-node positive disease, and adverse pathology. Early salvage RT (SRT) is typically a preferred treatment approach as it allows for treatment intensification only when clinically indicated, avoiding unnecessary radiation in men who may never recur. ADT is often added to external beam radiation therapy (EBRT) to enhance treatment efficacy, particularly in patients with high-risk features, though in selected lower-risk scenarios, radiation alone may be sufficient. Short-term ADT is appropriate for low-intermediate risk patients and long-term is appropriate for patients with advanced pathological features or nodal involvement. For certain high-risk pathologic findings, such as positive surgical margins and seminal vesicle invasion (T3b), adjuvant RT (aRT) may be indicated to optimize disease control. Overall, radio-hormone therapy plays a significant role in the postoperative setting by reducing the risk of recurrence and disease progression, and improving survival outcomes. There are several well-validated tools that may offer personalized risk assessments to identify which patients may most benefit from adjuvant or salvage therapies. Finally, the optimal use of such therapies continues to be investigated with ongoing trials.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the Needs of Breast Cancer Survivors. 解决乳腺癌幸存者的需要。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-13 DOI: 10.1007/s11912-025-01687-x

Humaira Sarfraz, Fatima Tuz Zahra, Utsav Joshi, Tracey O'Connor

{"title":"Addressing the Needs of Breast Cancer Survivors.","authors":"Humaira Sarfraz, Fatima Tuz Zahra, Utsav Joshi, Tracey O'Connor","doi":"10.1007/s11912-025-01687-x","DOIUrl":"https://doi.org/10.1007/s11912-025-01687-x","url":null,"abstract":"Introduction: Breast cancer survivors experience unique treatment-related side effects that have long-standing and life-altering implications. These remain a challenging aspect both in terms of diagnosis and management for these patients.Objective: This article is a review of the latest key literature in the management of common side effects of treatment in breast cancer survivors namely infertility, vasomotor symptoms, sexual dysfunction, peripheral neuropathy, lymphedema, musculoskeletal symptoms, anthracycline-related cardiotoxicity, secondary malignancies, role of ctDNA, lifestyle modifications, strategies to maintain bone mineral density and addressing fear of cancer recurrence.Results: Recent research in the field has led to novel advancements for survivors planning a family, pharmacotherapeutic options for hot flashes, overcoming barriers such as adherence to therapy and management of long-term side effects, and a incorporating a multimodal approach to improve sexual health in women, neuropathy, musculoskeletal issues and lymphedema. There have been significant strides in the understanding and management of issues in breast cancer survivors. The increasing awareness and multimodal approach will continue to improve outcomes for survivors.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0